Navigation Links
EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
Date:12/5/2007

Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU or that Ceplene, if approved, will not achieve significant commercial success, the risk that our NP-1 clinical trials will not be successful, that NP-1 will not receive regulatory approval or achieve significant commercial success, the risk that Myriad's development of Azixa(TM) will not be successful, the risk that Azixa(TM) will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for EPC 2407 will not be successful, that EPC 2407 will not receive regulatory approval or achieve significant commercial success, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with our need to raise additional financing to continue to meet our capital needs and our ability to continue as a going concern, the risks associated with dependence upon key personnel, the ri
'/>"/>
SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. EpiCept Corporation to Present at the 2007 BIO InvestorForum
2. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
3. EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
5. EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
6. EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
7. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
8. EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology
9. EpiCept Corporation Announces Pricing of Public Offering
10. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Pass, OR (PRWEB) July 31, 2014 Sales ... 12-percent from 2013 to 2014, according to radio talk show ... has been experiencing rapid growth since 1990. The US economy ... Sharon Kleyne Hour Power of Water radio show, reported this ... Bragg Live Foods, a worldwide manufacturer of organic and natural ...
(Date:7/31/2014)... According to new research report ... by Type (Tofu, Tofu-Based Product, Tempeh, TVP, Seitan, ... Trends & Forecasts to 2019", defines and segments ... and forecasting of the market value of sources, ... also identifies the driving and restraining factors for ...
(Date:7/31/2014)... July 31, 2014 Care Communications, Inc., ... outsourcing firm, has received the Elite Award for “Recruitment, ... Resources, one of twelve elite awards presented as part ... to Work For” 2014 awards competition. This marks ... Elite Award in the competition. CARE has also been ...
(Date:7/31/2014)... July 31, 2014 Daily Gossip reveals in ... help sufferers discover some breakthrough weight loss tips. , ... tips and recommendations are very simple to implement. Users don’t ... foods, with no need to start counting calories. , ... who in fact created a 12 weeks weight loss program ...
(Date:7/31/2014)... 31, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is looking at 10 tips to ... , “Addiction recovery is a lifelong process, and one that ... committed to without compromise,” commented Best Drug Rehabilitation’s CEO ...
Breaking Medicine News(10 mins):Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 3Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 2Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 3Health News:Care Communications, Inc. Named an Elite Award Winner Among Top Chicago Employers 2Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2
... century, John Snow mapped cases of cholera in Soho, London, ... water pump. Now, in a twenty-first century equivalent, scientists funded ... the latest in gene sequencing technology and global positioning system ... trace its source. Typhoid fever is caused by two ...
... Updated guidelines from the American Academy of Pediatrics (AAP) ... (ADHD) in younger children and in adolescents. Emerging ... in children from ages 4 to 18 (the previous ... 6 to 12). The new guidelines describe the special ...
... , SATURDAY, Oct. 15 (HealthDay News) -- Head injuries are ... a new study finds. Researchers examined data on 52 ... at a pediatric trauma center between 2003 and 2011. The ... 10 and the most common cause of injury was hitting ...
... BOSTON - An in-hospital delay of appendicitis treatment ... likelihood of complications, including perforation and abscess formation; ... according an abstract presented Saturday, Oct. 15 at ... and Exhibition in Boston. In "Missed Opportunities ...
... 14 (HealthDay News) -- Flu activity levels in the United ... get a flu shot, the U.S. Centers for Disease Control ... for the 2011-2012 flu season, the federal agency also said ... the U.S. supply is projected to be at an all-time ...
... One in six people in the United States is affected ... multiple sclerosis, and more research is required to find new ... mark its 20th anniversary, the foundation has released a video ... ongoing research. "Brain disease is in the news every ...
Cached Medicine News:Health News:Google Earth typhoid maps reveal secrets of disease outbreaks 2Health News:Google Earth typhoid maps reveal secrets of disease outbreaks 3Health News:AAP expands ages for diagnosis and treatment of ADHD in children 2Health News:Delayed pediatric appendicitis treatment linked to complications, and even death 2Health News:Get Your Flu Shot Now, CDC Urges 2Health News:Foundation Aims to Raise Awareness of Brain Diseases 2
(Date:7/30/2014)... Germany , July 30, 2014  invendo ... and computer-assisted ("robotic") colonoscopy system, today announced the appointment ... medical device executive, as a new member of its ... highly respected global visionary in the medical device industry. ... and Chief Executive Officer at Given Imaging Ltd. (NASDAQ/TASE: ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
(Date:7/30/2014)... VEGAS , July 30, 2014  DigiPath, Inc. ... that is expanding into the cannabis testing and education ... in its business and affairs not previously disclosed or, ... the recent unusual market action. "We have ... over the last three trading days," said Steve ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
... patient tracking and billing. ... complete Handheld application, a ... complete CPT™ and ICD-9-CM ... AMA. Designed for any ...
... ToolBox is an advanced medical ... Emergency, Pediatric Dosing and Critical ... is a logical complement to ... as the Daviss Drug Guide, ...
... the handheld version of ... drug interaction analyzer covering ... generic drugs. iFacts™ enables ... to accurate and reliable ...
A handy, quick reference for physicians, nurses, and other health care providers treating cancer patients....
Medicine Products: